학술논문

EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 543건 | 목록 1~20
Academic Journal
Bastick, PatriciaSewak, SanjeevTran, BenPichler, MartinShariat, ShahrokhRottey, SylvieSchatteman, PeterSchrijvers, DirkVerschaeve, VincentVulsteke, ChristofBarros Leite Ferreira, Luiza Aleixode Santana Gomes Andrea Juliana, PereiraJunior, Joao AntonioAzevedo, SergioBastos, DiogoBorges, GiulianoDettino, AldoAntonio, Pires LuisLuz, MuriloMartins, SuelenMota, Jose MauricioToledo, JoseaneEigl, BernhardFinch, DaygenGingerich, JoelDong, HaiyingHuang, JianJin, JiePan, HongmingSun, ZhongquanTian, YeWan, BenWu, BinXu, TingXue, WeiZhou, FangjianBarthelemy, PhilippeBorchiellini, DelphineCalcagno, FabienCarnot, AurelienCornillon, PierreDelva, RemyEmambux, SheikHouede, NadineLaguerre, BrigitteLauridant, GéraldineLoriot, YohannMahammedi, HakimMaillet, DenisPouessel, DamienRoubaud, GuilhemSchlurmann-Constans, FriederikeTosi, DiegoZanetta, SylvieBanek, SeverineFeyerabend, SusanKramer, MarioNiegisch, GuentherNuhn, PhilippSchnabel, MarcoWuelfing, ChristianBaka, SofiaBamias, AristotelisFountzilas, GeorgeKalofonos, HarabolosKaralis, KonstantinosKotsakis, AthanasiosTimotheadou, EleniLandherr, LaszloMangel, LaszloPe’er, AvivitLevratovsky, MeitalBasso, UmbertoBattelli, NicolaCavo, AlessiaDe Giorgi, UgoDoni, LauraGalli, LucaGigante, Maria OlgaGuadalupi, ValentinaMaio, MicheleMilesi, LauraNolè, FrancoScagliotti, GiorgioTortora, GiampaoloFukasawa, SatoshiHarabayashi, ToruKamiya, NaotoKawahara, TakashiKawakita, MutsushiMatsubara, NobunakiMatsumoto, KazumasaNishimura, KazuoRikiya, TaokaShimizu, NobuakiTagaki, ToshioKang, Taek WonKim, Jwa HoonKim, SeHyunLee, Hyo JinLee, Yun-GyooRha, Sun YoungSeo, Ho KyungLos, MaartjeZurawski, BogdanCortes, PauloFaustino, CatiaVau, Nuno Sineiroda Luz, RicardoAtduev, VagifKirtbaya, DmitryKopyltsov, EvgenyLykov, AleksandrMarat, UrmantsevOrlov, SergeyPenkov, KonstantinPirmagomedov, AlbertSemenov, AndreyVarlamov, SergeyAnguera, GeorgiaDomenech, MontserratGirones, ReginaGonzalez del Alba, AranzazuMilagro, Nuria LainezLuque, RaquelOrtega, Esther MartínezMellado, BegoñaMéndez Vidal, María JoseFernandez, Esteban NogalesValderrama, Begoña PerezMarín, Alvaro PintoSantander, CarmenHuang, Yi-HsiuSu, Wen-PinWu, Hung-ChanWu, WenJengYu, Kai-JieBilici, AhmetGoker, ErdemGumus, MahmutKaraoglu, AzizKefeli, UmutKöse, FatihOzguroglu, MustafaTural, DenizTurk, HaciYalcin, SuayibBondarenko, IgorKhareba, GennadiiKidik, YanaLychkovskyy, OleksandrSakalo, ValeriiShevnia, SerghiiStakhovskyy, EduardBahl, AmitCrabb, SimonPowles, ThomasSankey, PeterSarwar, MohammadBenedetto, PasqualeBurgess, EarleDawson, NancyDoshi, GurjyotFleming, MarkMaly, JosephParikh, MamtaWaterhouse, DavidSiefker-Radtke, A.O.Matsubara, N.Park, S.H.Huddart, R.A.Burgess, E.F.Özgüroğlu, M.Valderrama, B.P.Laguerre, B.Basso, U.Triantos, S.Akapame, S.Kean, Y.Deprince, K.Mukhopadhyay, S.Loriot, Y.
In Annals of Oncology January 2024 35(1):107-117
Academic Journal
Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.; Triantos S; Janssen Research & Development, Spring House, PA, USA.; Deprince K; Janssen Research & Development, Beerse, Belgium.; Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: In Process; MEDLINE
Academic Journal
Demirdjian L; Janssen Research & Development, Spring House, Pennsylvania, USA.; Triantos S; Janssen Research & Development, Spring House, Pennsylvania, USA.; Standish K; Janssen Research & Development, Spring House, Pennsylvania, USA.; Thomas S; Janssen Research & Development, Spring House, Pennsylvania, USA.; Xia Q; Janssen Research & Development, Spring House, Pennsylvania, USA.; Zhang J; Janssen Research & Development, Spring House, Pennsylvania, USA.; Greshock J; Janssen Research & Development, Spring House, Pennsylvania, USA.; Paone J; Aetion, New York, New York, USA.; Sheridan P; Aetion, New York, New York, USA.; Pant S; The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.; Massard C; Gustave Roussy, Université Paris Saclay, Villejuif, France.; Reardon DA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Loriot Y; Gustave Roussy, Université Paris Saclay, Villejuif, France.; Schuler M; West German Cancer Center, University Hospital Essen, Essen, Germany.; Sweiti H; Janssen Research & Development, Spring House, Pennsylvania, USA.
Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
Academic Journal
Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. Electronic address: nmatsuba@east.ncc.go.jp.; Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.; Burgess EF; Department of Medical Oncology, Levine Cancer Institute, North Carolina, USA.; Park SH; Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.; Huddart RA; Department of Medical Oncology, Levine Cancer Institute, North Carolina, USA; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK.; Ku JH; Department of Urology, Seoul National University Hospital, Seoul, South Korea.; Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Huang J; Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.; Huang YH; Department of Urology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan.; Nishimura K; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.; Shimizu N; Department of Urology, Gunma Prefectural Cancer Center, Gunma, Japan.; Xing N; Department of Urology, National Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, Beijing, China.; Xue W; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Hemaya R; Janssen Medical Affairs Asia Pacific, Victoria, Australia.; Zhuo J; Janssen Research & Development, Shanghai, China.; Deprince K; Janssen Research & Development, Beerse, Belgium.; Triantos S; Janssen Research & Development, Spring House, Pennsylvania, USA.; Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA.
Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE
Electronic Resource
Siefker-Radtke, A. O.Matsubara, N.Park, S. H.Huddart, R. A.Burgess, E. F.Ozguroglu, M.Valderrama, B. P.Laguerre, B.Basso, U.Triantos, S.Akapame, S.Kean, Y.Deprince, K.Mukhopadhyay, S.Loriot, Y.Bastick, P.Sewak, S.Tran, B.Pichler, M.Shariat, S.Rottey, S.Schatteman, P.Schrijvers, D.Verschaeve, V.Vulsteke, C.Barros Leite Ferreira, L. A.de Santana Gomes Andrea Juliana, P.Junior, J. A.Azevedo, S.Bastos, D.Borges, G.Dettino, A.Antonio, P. L.Luz, M.Martins, S.Mota, J. M.Toledo, J.Eigl, B.Finch, D.Gingerich, J.Dong, H.Huang, J.Jin, J.Pan, H.Sun, Z.Tian, Y.Wan, B.Wu, B.Xu, T.Xue, W.Zhou, F.Barthelemy, P.Borchiellini, D.Calcagno, F.Carnot, A.Cornillon, P.Delva, R.Emambux, S.Houede, N.Lauridant, G.Mahammedi, H.Maillet, D.Pouessel, D.Roubaud, G.Schlurmann-Constans, F.Tosi, Domiziano DarioZanetta, S.Banek, S.Feyerabend, S.Kramer, M.Niegisch, G.Nuhn, P.Schnabel, M.Wuelfing, C.Baka, S.Bamias, A.Fountzilas, G.Kalofonos, H.Karalis, K.Kotsakis, A.Timotheadou, E.Landherr, L.Mangel, L.Pe'Er, A.Levratovsky, M.Battelli, N.Cavo, A.De Giorgi, U.Doni, L.Galli, L.Gigante, M. O.Guadalupi, V.Maio, M.Milesi, L.Nole, F.Scagliotti, G.Tortora, GiampaoloFukasawa, S.Harabayashi, T.Kamiya, N.Kawahara, T.Kawakita, M.Matsumoto, K.Nishimura, K.Rikiya, T.Shimizu, N.Tagaki, T.Kang, T. W.Kim, J. H.Kim, S.Lee, H. J.Lee, Y. -G.Rha, S. Y.Seo, H. K.Los, M.Zurawski, B.Cortes, P.Faustino, C.Vau, N. S.da Luz, R.Atduev, V.Kirtbaya, D.Kopyltsov, E.Lykov, A.Marat, U.Orlov, S.Penkov, K.Pirmagomedov, A.Semenov, A.Varlamov, S.Anguera, G.Domenech, M.Girones, R.Gonzalez del Alba, A.Milagro, N. L.Luque, R.Ortega, E. M.Mellado, B.Mendez Vidal, M. J.Fernandez, E. N.Marin, A. P.Santander, C.Huang, Y. -H.Su, W. -P.Wu, H. -C.Wu, W.Yu, K. -J.Bilici, A.Goker, E.Gumus, M.Karaoglu, A.Kefeli, U.Kose, F.Tural, D.Turk, H.Yalcin, S.Bondarenko, I.Khareba, G.Kidik, Y.Lychkovskyy, O.Sakalo, V.Shevnia, S.Stakhovskyy, E.Bahl, A.Crabb, S.Powles, T.Sankey, P.Sarwar, M.Benedetto, P.Burgess, E.Dawson, N.Doshi, G.Fleming, M.Maly, J.Parikh, M.Waterhouse, D.Tosi D.Tortora G. (ORCID:0000-0002-1378-4962)
Academic Journal
Eisner JR; GeneCentric Therapeutics, Inc., Durham, North Carolina.; de Jong FC; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Shibata Y; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Mayhew GM; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Davison JM; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Carcione J; Janssen Research & Development, LLC, A Johnson & Johnson Company, New Brunswick, New Jersey.; Pappan KL; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Thomas S; Janssen Research & Development, LLC, A Johnson & Johnson Company, New Brunswick, New Jersey.; Triantos S; Janssen Research & Development, LLC, A Johnson & Johnson Company, New Brunswick, New Jersey.; Santiago-Walker A; Janssen Research & Development, LLC, A Johnson & Johnson Company, New Brunswick, New Jersey.; Baig M; Janssen Research & Development, LLC, A Johnson & Johnson Company, New Brunswick, New Jersey.; Milburn MV; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Beebe KD; GeneCentric Therapeutics, Inc., Durham, North Carolina.; Zuiverloon TCM; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Electronic Resource
Pant, SSchuler, MIyer, GWitt, ODoi, TQin, STabernero, JReardon, DMassard, CMinchom, ALugowska, ICarranza, OArnold, DGutierrez, MWinter, HStuyckens, KCrow, LNajmi, SHammond, CThomas, SSantiago-Walker, ATriantos, SSweiti, HLoriot, YGreco, MCoward, JJoshua, AKarapetis, CHart, CZhang, APrenen, HGoeminne, JMachiels, JRottey, SCorassa, MMolin, GTiscoski, KJardim, DMak, MFu, WYao, HHuang, JJiang, HChen, BYan, DYang, YLe Tourneau, CPenel, NSalas, SBlay, JBrachet, PDurando, XEmambux, SRavaud, AFolprecht, GAhrens, MGolf, AHaag, GLordick, FDesuki, ACazzaniga, MCiardiello, FMilella, MKoyama, THirooka, YOkamoto, WAogi, KKuboki, YLee, JKim, SAhn, MChang, JKim, YNam, DPark, JPaz-Ares, LMoreno, VCervantes, ACalvo, MFalcon, AGonzalez, AMartinez Bueno, AGarcia-Corbacho, JLongo, FYen, CChen, JHou, MChao, YRau, KChiu, TFeng, YHsu, CHuang, WLai, KYeh, SPalmer, DWelsh, LPlummer, RBilen, MArrowsmith, ESpigel, DZandberg, DDoroshow, DLu-Emerson, CMoezi, MPaulson, SWard, PChaves, JGrigg, CHussein, AManda, SMonticelli, MQamar, RRichey, STamura, DWilks, SPant S.Schuler M.Iyer G.Witt O.Doi T.Qin S.Tabernero J.Reardon D. A.Massard C.Minchom A.Lugowska I.Carranza O.Arnold D.Gutierrez M.Winter H.Stuyckens K.Crow L.Najmi S.Hammond C.Thomas S.Santiago-Walker A.Triantos S.Sweiti H.Loriot Y.Greco M. A.Coward J.Joshua A.Karapetis C.Hart C.Zhang A.Prenen H.Goeminne J. -C.Machiels J. -P.Rottey S.Corassa M.Molin G. Z. D.Tiscoski K.Jardim D. L. F.Mak M.Fu W.Yao H.Huang J.Jiang H.Chen B.Yan D.Yang Y.Le Tourneau C.Penel N.Salas S.Blay J. -Y.Brachet P. -E.Durando X.Emambux S.Ravaud A.Folprecht G.Ahrens M.Golf A.Haag G. M.Lordick F.Desuki A.Cazzaniga M.Ciardiello F.Milella M.Koyama T.Hirooka Y.Okamoto W.Aogi K.Kuboki Y.Lee J.Kim S. -B.Ahn M. -J.Chang J. H.Kim Y. -M.Nam D. -H.Park J. -S.Paz-Ares L.Moreno V.Cervantes A.Calvo M.Falcon A.Gonzalez A.Martinez Bueno A.Garcia-Corbacho J.Longo F.Yen C. -J.Chen J. -S.Hou M. -F.Chao Y.Rau K. -M.Chiu T. -J.Feng Y. -H.Hsu C. -H.Huang W. -T.Lai K. -M.Yeh S. -P.Palmer D.Welsh L.Plummer R.Bilen M.Arrowsmith E.Spigel D. R.Zandberg D. P.Doroshow D.Lu-Emerson C.Moezi M.Paulson S.Reardon D.Ward P.Chaves J.Grigg C.Hussein A.Manda S.Monticelli M.Qamar R.Richey S. L.Tamura D.Wilks S.
Academic Journal
Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. nmatsuba@east.ncc.go.jp.; Miura Y; Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan.; Nishiyama H; Department of Urology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.; Taoka R; Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.; Kojima T; Department of Urology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.; Shimizu N; Department of Urology, Gunma Prefectural Cancer Center, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.; Hwang J; Department of Medical Affairs, Janssen Pharmaceutical K.K, 5-2-3 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan.; Ote T; Oncology Clinical Development Department, Clinical Science Division, Research and Development, Janssen Pharmaceutical K.K, 5-2-3 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan.; Oyama R; Research and Development, Janssen Pharmaceutical K.K, 5-2-3 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan.; Toyoizumi K; Statistics and Decision Sciences, Research and Development, Janssen Pharmaceutical K. K, 5-2-3 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan.; Mukhopadhyay S; Janssen Research and Development, 920 US Highway 202 S, Raritan, NJ, 08807, USA.; Triantos S; Janssen Research and Development, 1400 McKean Road, Spring House, PA, 19477, USA.; Deprince K; Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse Anterwerpen, Belgium.; Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Universite Paris-Saclay, 94800, Villejuif, France.
Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE
Academic Journal
Zhu W; Janssen Research & Development, Raritan, NJ, USA.; Baig M; Janssen Research & Development, Bridgewater, NJ, USA.; Naini V; Janssen Research & Development, San Diego, CA, USA.; De Meulder M; Janssen Research & Development, Beerse, Belgium.; Akapame S; Janssen Research & Development, Raritan, NJ, USA.; De Zwart L; Janssen Research & Development, Beerse, Belgium.; Haddish-Berhane N; Janssen Research & Development, Spring House, PA, USA.; Triantos S; Janssen Research & Development, Spring House, PA, USA.
Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2160-7648 (Electronic) Linking ISSN: 2160763X NLM ISO Abbreviation: Clin Pharmacol Drug Dev Subsets: MEDLINE
Academic Journal
Van Sanden S; Janssen Pharmaceutica NV, Beerse, Belgium.; Youssef A; Janssen Cilag, Issy-les-Moulineaux, France.; Baculea S; Janssen Cilag Ltd, High Wycombe, United Kingdom.; Stubbs K; Janssen Cilag Ltd, High Wycombe, United Kingdom.; Triantos S; Johnson & Johnson, Spring House, Pennsylvania, United States.; Yuan Z; Cytel Inc., Rotterdam, Netherlands.; Daly C; Cytel Inc., Toronto, Ontario, Canada.
Publisher: Columbia Data Analytics, LLC Country of Publication: United States NLM ID: 101648581 Publication Model: eCollection Cited Medium: Internet ISSN: 2327-2236 (Electronic) Linking ISSN: 2326697X NLM ISO Abbreviation: J Health Econ Outcomes Res Subsets: PubMed not MEDLINE
Academic Journal
Loriot Y; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Matsubara N; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Park SH; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Huddart RA; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Burgess EF; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Houede N; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Banek S; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Guadalupi V; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Ku JH; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Valderrama BP; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Tran B; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Triantos S; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Kean Y; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Akapame S; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Deprince K; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Mukhopadhyay S; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Stone NL; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).; Siefker-Radtke AO; From the Department of Cancer Medicine, INSERM Unité 981, Gustave Roussy, Université Paris-Saclay, Villejuif (Y.L.), the Department of Medical Oncology, Institut de Cancérologie du Gard, Centre Hospitalier Universitaire Caremeau, Nîmes (N.H.), and Montpellier University, Montpellier (N.H.) - all in France; the Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan (N.M.); the Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Seoul National University Hospital (J.H.K.) - both in Seoul, South Korea; the Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom (R.A.H.); Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC (E.F.B.); the Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany (S.B.); the Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (V.G.); the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.T.); Janssen Research and Development, Spring House, PA (S.T., Y.K., S.A., N.L.S.); Janssen Research and Development, Beerse, Belgium (K.D.); Janssen Research and Development, Raritan, NJ (S.M.); and the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (A.O.S.-R.).
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
Academic Journal
Pant S; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: spant@mdanderson.org.; Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.; Iyer G; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.; Witt O; Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, German Cancer Research Center and National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Doi T; National Cancer Center Hospital East, Kashiwa, Japan.; Qin S; Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.; Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, Barcelona, Spain.; Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Massard C; Le Kremlin Bicêtre-France INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, Paris, France.; Minchom A; The Royal Marsden NHS Foundation Trust, Sutton, UK.; Lugowska I; Department of Soft Tissue/Bone Sarcoma and Melanoma, Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warsaw, Poland.; Carranza O; Hospital Privado de Comunidad de Mar del Plata, Mar del Plata, Argentina.; Arnold D; Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany.; Gutierrez M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.; Winter H; Bristol Haematology and Oncology Centre, Bristol, UK.; Stuyckens K; Janssen Research & Development, Beerse, Belgium.; Crow L; Janssen Research & Development, Spring House, PA, USA.; Najmi S; Janssen Research & Development, Spring House, PA, USA.; Hammond C; Janssen Research & Development, Spring House, PA, USA.; Thomas S; Janssen Research & Development, Spring House, PA, USA.; Santiago-Walker A; Janssen Research & Development, Spring House, PA, USA.; Triantos S; Janssen Research & Development, Spring House, PA, USA.; Sweiti H; Janssen Research & Development, Spring House, PA, USA.; Loriot Y; Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: Yohann.LORIOT@gustaveroussy.fr.
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Triantos, S.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어